Addiction Research Publication Announces New Editor In Chief
American Society of Addiction Medicine appoints Dr. David A. Fiellin to lead the Journal of Addiction Medicine, its official scientific journal.
Rockville, MD, November 2, 2022 – Today, the American Society of Addiction Medicine (ASAM) named David A. Fiellin, MD, FASAM, the next editor in chief of its Journal of Addiction Medicine (JAM).
Dr. Fiellin is an internist, board certified in addiction medicine. He is professor of Medicine and Emergency Medicine at Yale School of Medicine, and Public Health at Yale School of Public Health; vice chief of Faculty Affairs for the Department of Internal Medicine’s Section of General Internal Medicine; and serves as the inaugural director of the Program in Addiction Medicine at Yale.
Dr. Fiellin has focused his scholarly work on improving access to and the quality of substance use prevention and treatment, especially in general healthcare settings. His research focuses on the efficacy, effectiveness, and implementation of treatments for opioid use disorder and alcohol use disorder in office-based, primary care, Emergency Department, hospital, obstetrical and gynecologic practices, and HIV specialty settings. He has served and is serving as principal investigator and co-investigator on multiple NIH-funded research projects using a variety of research designs including clinical trials, observational studies, pharmacoepidemiology, qualitative methods, and implementation science. His work has been published in journals that include NEJM, JAMA, The Lancet, Annals of Internal Medicine, and BMJ.
“ASAM is proud to have Dr. Fiellin lead its scientific journal and looks forward to his shaping the future of addiction medicine research,” Nicholas Athanasiou, MD, MBA, DFASAM, ASAM Publications Council chair, and chair of the position’s recruitment effort. “With his expertise in research and education, combined with over fifteen years of experience serving on the editorial boards of the Journal of Addiction Medicine, Journal of Substance Abuse Treatment, and Substance Abuse and serving as the co-editor of the newsletter, Alcohol, Other Drugs & Health: Current Evidence, he will skillfully guide the Journal of Addiction Medicine at a remarkable time for the field and publication.”
“The Journal of Addiction Medicine continues to gain prominence in the field. Dr. Fiellin has the strong medical and research background to continue the incredible growth of ASAM’s journal that we experienced under Dr. Saitz’s leadership,” said Bill Haning, MD, DLFAPA, DFASAM, president of ASAM. “Over recent decades, the Journal of Addiction Medicine has quickly become a leading addiction journal, having gained inclusion in MEDLINE/PubMed and gone from a quarterly to a bimonthly periodical.”
In addition to his other experience, Dr. Fiellin was a co-editor for ASAM Principles of Addiction Medicine, 4-6th Editions, 2009-2018. He received the prestigious Dan Anderson Research Award from Hazelden-Betty Ford Foundation in 2016. He also received the W. Anderson Spickard Jr. Excellence in Mentorship Award from AMERSA in 2014. Other awards received include ASAM’s Annual Award and the Nyswander/Dole Award.
Dr. Fiellin will begin the leadership position in January of 2023, when the acting interim editor in chief, renowned researcher, Frank J. Vocci, PhD, steps down to focus on research related to developing medications for the treatment of substance use disorders. Dr. Fiellin will join current journal co-editors Drs. Kelly E. Dunn, Ismene Petrakis, and Frank J. Vocci, and acting co-editors Benjamin H. Han and Marcela Smid.
About the Journal of Addiction Medicine
The Journal of Addiction Medicine (JAM) is the official journal of the American Society of Addiction Medicine and is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. The mission of the JAM is to promote excellence in the practice of addiction medicine and clinical research as well as to support addiction medicine as a mainstream medical specialty. Published bimonthly, the Journal is designed to engage clinicians in advancing the assessment, treatment, and understanding of the disease of addiction. Under the guidance of an esteemed editorial board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics.
About the American Society of Addiction Medicine
The American Society of Addiction Medicine (ASAM), founded in 1954, is a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access to and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction. For more information, visit www.ASAM.org.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for various regulatory sectors. In the healthcare field, WKL provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, and students in effective decision-making and outcomes. Wolters Kluwer supports clinical effectiveness, learning, and research, along with clinical surveillance and compliance, as well as data solutions. WKL reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
Contact: Christine Merrifield, press@ASAM.org, 301-547-4140